SOUTH SAN FRANCISCO, Calif.,
March 1, 2022 /PRNewswire/
-- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic
lethality focused precision medicine oncology company committed to
the discovery and development of targeted therapeutics, announced
its participation in investor conferences in March 2022.
Guggenheim 3rd Annual Healthy Altitudes CEO Summit
Panel
Thursday, March 10 at 9:00am ET
Participation by Yujiro Hata, Chief Executive Officer, IDEAYA
Biosciences, moderated by Dan
Skovronsky, M.D. Ph.D. CSO, Eli Lilly with host Seamus Fernandez, Senior Managing Director and
Global Biopharma Analyst, Guggenheim Securities
Oppenheimer Targeted Oncology Panel
Monday, March 14, 10:00am ET
Participation by Yujiro Hata, Chief Executive Officer, IDEAYA
Biosciences, hosted by Kevin DeGeeter Managing Director and Senior
Analyst, Biotechnology and Diagnostics, Oppenheimer
34th Annual Roth Conference
Monday, March 14, 2022 at
6:00pm ET
Fireside chat with Paul Stone, Chief Financial Officer, IDEAYA
Biosciences, hosted by Zegbeh Jallah Ph.D. Managing Director,
Research Analyst, Biotechnology Roth Capital Partners
Oppenheimer's 32nd Annual Healthcare Conference
Wednesday, March 16, 2022 at
10:40am ET
Presentation by Yujiro Hata, Chief Executive Officer, IDEAYA
Biosciences
A live audio webcast of the event will be available, as
permitted by conference host, at the "Investors/News and
Events/Investor Calendar" section of the IDEAYA website at
https://ir.ideayabio.com/events. A replay of available
webcasts will be accessible for 30 days following the live
event.
About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics for patient populations selected using
molecular diagnostics. IDEAYA's approach integrates
capabilities in identifying and validating translational biomarkers
with drug discovery to select patient populations most likely to
benefit from its targeted therapies. IDEAYA is applying its
early research and drug discovery capabilities to synthetic
lethality – which represents an emerging class of precision
medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to participation
in and/or presentation at certain investor relations events. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's
Quarterly Report on Form 10-Q filed on November 15, 2021 and any current and periodic
reports filed with the U.S. Securities and Exchange Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-investor-conferences-in-march-2022-301492459.html
SOURCE IDEAYA Biosciences, Inc.